Data Science Funding Announcements & Notices
Data science and informatics funding announcements and notices are available from NCI and NIH programs. Browse below for opportunities, requests for information, notices, and initiatives.
| Title | FOA | Organization | Release Date | Expire Date Sort descending | Purpose |
|---|---|---|---|---|---|
| Chemical Countermeasures Research Program (CCRP) Initiative: Basic Research on The Deleterious Effects of Acute Exposure to Ultra-Potent Synthetic (UPS) Opioids (R01 Clinical Trial Not Allowed) | RFA-DA-23-056 | NIDA | This Funding Opportunity Announcement (FOA) will support transformative research to identify and validate mechanisms, signaling pathways, and therapeutic targets, for understanding and reversing the… More | ||
| The Intersection of Sex and Gender Influences on Health and Disease (R01 Clinical Trial Optional) | RFA-OD-22-028 | ORWH | The purpose of this Funding Opportunity Announcement (FOA) is to invite R01 applications on the influence and intersection of sex and gender in health and disease including: (1) research applications… More | ||
| Research Experiences to Enhance Clinician-Scientists' Participation in NIDCDs Research (R25 Clinical Trial Not Allowed) | PAR-21-188 | NIDCD | The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The overarching goal of this R25 program is to support educational activities that… More | ||
| NIDCD's Mentoring Networks to Enhance Clinician-Scientists' Participation in Research (R25 Clinical Trial Not Allowed) | PAR-21-187 | NIDCD | The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The overarching goal of this R25 program is to support educational activities that… More | ||
| Method to Extend Research in Time (MERIT) Award Extension Request (Type 4 Clinical Trial Optional) | PAR-21-138 | NCI | The National Cancer Institute (NCI) Method to Extend Research in Time (MERIT) (R37) Award provides extended grant support to Early Stage Investigators (ESIs). By providing such an opportunity for… More | ||
| Translational Research Toward Development of a Kaposi Sarcoma Herpesvirus (KSHV) Vaccine (U01 Clinical Trial Optional) | RFA-CA-24-006 | NCI | Through this Notice of Funding Opportunity Announcement (NOFO), the National Cancer Institute (NCI) intends to expand the research scope and leverage the gains made through the NOFO entitled… More | ||
| Investigational New Drug (IND)-enabling and Early-Stage Development of Medications to Treat Alcohol Use disorder and Alcohol-Associated Organ Damage (U43/U44 Clinical Trial Optional) | PAR-22-102 | NIAAA | This Funding Opportunity Announcement (FOA) supports Small Business Innovation Research (SBIR) applications from small business concerns (SBCs) that propose the development of therapeutic agents for… More | ||
| Investigational New Drug (IND)-enabling and Early-Stage Development of Medications to Treat Alcohol Use disorder and Alcohol-Associated Organ Damage (UT1/UT2 Clinical Trial Optional) | PAR-22-103 | NIAAA | This Funding Opportunity Announcement (FOA) supports Small Business Technology Transfer (STTR) applications from small business concerns (SBCs) that propose the development of therapeutic agents for… More | ||
| HEAL Initiative: Discovery and Validation of Novel Targets for Safe and Effective Pain Treatment (R01 Clinical Trial Not Allowed) | RFA-NS-22-034 | NINDS | The purpose of this Funding Opportunity Announcement (FOA) is to promote the discovery and validation of novel therapeutic targets to facilitate the development of pain therapeutics. Specifically,… More | ||
| Next Generation Multipurpose Prevention Technologies (NGM) (R01 Clinical Trial Optional) | PAR-23-180 | NIAID | The objective of this Notice of Funding Opportunity (NOFO) is to support the continued development of new and innovative on-demand, event-driven, and long-acting (systemic and non-systemic)… More |